COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARδ activation

Although cyclooxygenase (COX)-2 inhibitors (coxibs) are effective in controlling inflammation, pain, and tumorigenesis, their use is limited by the recent revelation of increased adverse cardiovascular events. The mechanistic basis of this side effect is not well understood. We show that the metabolism of endocannabinoids by the endothelial cell COX-2 coupled to the prostacyclin (PGI2) synthase (PGIS) activates the nuclear receptor peroxisomal proliferator–activated receptor (PPAR) δ, which negatively regulates the expression of tissue factor (TF), the primary initiator of blood coagulation. Coxibs suppress PPARδ activity and induce TF expression in vascular endothelium and elevate circulating TF activity in vivo. Importantly, PPARδ agonists suppress coxib-induced TF expression and decrease circulating TF activity. We provide evidence that COX-2–dependent attenuation of TF expression is abrogated by coxibs, which may explain the prothrombotic side-effects for this class of drugs. Furthermore, PPARδ agonists may be used therapeutically to suppress coxib-induced cardiovascular side effects.

[1]  W. S. Ho,et al.  Endothelium‐dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2‐arachidonoylglycerol , 2007, British journal of pharmacology.

[2]  J. Perez-polo,et al.  Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat heart. , 2007, Prostaglandins & other lipid mediators.

[3]  W. Wahli,et al.  Crosstalk between peroxisome proliferator-activated receptor δ and VEGF stimulates cancer progression , 2006, Proceedings of the National Academy of Sciences.

[4]  J. Freyssinet,et al.  Procoagulant Microparticles: Disrupting the Vascular Homeostasis Equation? , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[5]  S. Solomon,et al.  Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas , 2006, Circulation.

[6]  L. Køber,et al.  Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction , 2006, Circulation.

[7]  S. Suissa,et al.  Use of First- and Second-Generation Cyclooxygenase-2–Selective Nonsteroidal Antiinflammatory Drugs and Risk of Acute Myocardial Infarction , 2006, Circulation.

[8]  T. Lüscher,et al.  Tissue Factor in Cardiovascular Diseases: Molecular Mechanisms and Clinical Implications , 2006, Circulation.

[9]  Garret A FitzGerald,et al.  Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. , 2005, The Journal of clinical investigation.

[10]  Rajesh C. Dash,et al.  Prostacyclin protects against elevated blood pressure and cardiac fibrosis. , 2005, Cell metabolism.

[11]  Lawrence J Marnett,et al.  Glycerylprostaglandin Synthesis by Resident Peritoneal Macrophages in Response to a Zymosan Stimulus* , 2005, Journal of Biological Chemistry.

[12]  F. Peale,et al.  A monoclonal antibody that inhibits mouse tissue factor function , 2005, Journal of thrombosis and haemostasis : JTH.

[13]  F. Ruschitzka,et al.  Celecoxib Decreases Endothelial Tissue Factor Expression Through Inhibition of c-Jun Terminal NH2 Kinase Phosphorylation , 2005, Circulation.

[14]  J. Falck,et al.  Endothelium-derived 2-arachidonylglycerol: an intermediate in vasodilatory eicosanoid release in bovine coronary arteries. , 2005, American journal of physiology. Heart and circulatory physiology.

[15]  D. Rader,et al.  COX-2-Derived Prostacyclin Confers Atheroprotection on Female Mice , 2004, Science.

[16]  L. Marnett,et al.  Aberrant cannabinoid signaling impairs oviductal transport of embryos , 2004, Nature Medicine.

[17]  R. Proia,et al.  Sphingosine 1-phosphate receptor regulation of N-cadherin mediates vascular stabilization. , 2004, Genes & development.

[18]  R. Botting,et al.  Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition , 2004, Pharmacological Reviews.

[19]  R. Hebbel,et al.  Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. , 2004, Blood.

[20]  N. Mackman Role of tissue factor in hemostasis, thrombosis, and vascular development. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[21]  G. FitzGerald Prostaglandins: Modulators of Inflammation and Cardiovascular Risk , 2004, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[22]  J. Mitchell,et al.  Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  Rajnish A. Gupta,et al.  Activation of nuclear hormone receptor peroxisome proliferator–activated receptor-δ accelerates intestinal adenoma growth , 2004, Nature Medicine.

[24]  C. Patrono,et al.  Cyclooxygenase-2 Expression and Inhibition in Atherothrombosis , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[25]  B. Agarwal,et al.  Cox-2 is needed but not sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells , 2003, Apoptosis.

[26]  William A. Boisvert,et al.  Transcriptional Repression of Atherogenic Inflammation: Modulation by PPARδ , 2003, Science.

[27]  L. Marnett,et al.  Amino Acid Determinants in Cyclooxygenase-2 Oxygenation of the Endocannabinoid 2-Arachidonylglycerol* , 2001, The Journal of Biological Chemistry.

[28]  T. Willson,et al.  Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Ward,et al.  Growth, Adipose, Brain, and Skin Alterations Resulting from Targeted Disruption of the Mouse Peroxisome Proliferator-Activated Receptor β(δ) , 2000, Molecular and Cellular Biology.

[30]  T. Hla,et al.  Overexpression of Cyclooxygenase-2 Induces Cell Cycle Arrest , 1999, The Journal of Biological Chemistry.

[31]  J. Morrow,et al.  Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. , 1999, Genes & development.

[32]  T. Hla,et al.  Endothelial Cell Apoptosis Induced by the Peroxisome Proliferator-activated Receptor (PPAR) Ligand 15-Deoxy-Δ12,14-prostaglandin J2 * , 1999, The Journal of Biological Chemistry.

[33]  G. FitzGerald,et al.  Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Jasmine Chen,et al.  The Peroxisome Proliferator‐activated Receptors: Ligands and Activators a , 1996, Annals of the New York Academy of Sciences.

[35]  M. Gimbrone,et al.  Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[36]  E. Remmers,et al.  Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. , 1994, The Journal of clinical investigation.

[37]  T. Hla,et al.  Human cyclooxygenase-2 cDNA. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[38]  T. Edgington,et al.  Monoclonal antibody analysis of purified and cell-associated tissue factor. , 1988, Thrombosis research.

[39]  W. Frishman Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2006 .

[40]  F. Bermúdez-Silva,et al.  The endocannabinoid system: physiology and pharmacology. , 2005, Alcohol and alcoholism.

[41]  N. Ueda Endocannabinoid hydrolases. , 2002, Prostaglandins & other lipid mediators.